Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay Prasad as the director of CBER. We also talk about President Trump’s executive order about federal research grants, see advocates call for a Vertex probe in South Africa, and more.
That was fast: Vinay Prasad is back at CBER
Vinay Prasad is returning to lead the biologics division of the FDA just two weeks after his ouster, which followed a right-wing campaign criticizing his past liberal-leaning posts as well as reported White House intervention. His reinstatement, confirmed by HHS, comes after FDA Commissioner Marty Makary urged him to consider returning, STAT’s Lizzy Lawrence writes.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in